Head-to-head evidence
BCMA CAR-NK (Shenzhen Pregene Biopharma) vs Belantamab mafodotin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
BCMA CAR-NK (Shenzhen Pregene Biopharma)
Developed by Shenzhen Pregene Biopharma Co., Ltd.
NCT05652530 · Phase 1 · status unknown
This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 19 participants, and it measured only safety. Results have not been posted yet.
Belantamab mafodotin
Marketed by GlaxoSmithKline
NCT03525678 · Phase 2 · completed
This was a randomized but open-label phase 2 study in which all participants received belantamab mafodotin at one of two doses or formulations; there was no placebo or active comparator arm and no blinding. The primary endpoint was overall response rate by independent review, a clinical response measure, but the results are reported as per-arm rates with confidence intervals and no formal statistical comparison against a control, so the study cannot distinguish drug effect from natural history or placebo effect. The evidence is therefore descriptive phase 2 evidence of activity, not strong comparative evidence.
Next expected readout: October 2026 · NCT05573802 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCMA CAR-NK (Shenzhen Pregene Biopharma)'s landscape · Belantamab mafodotin's landscape